Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Antidiabetic agents.

G E Francisco1

  • 1College of Pharmacy, University of Georgia, Athens.

Primary Care
|September 1, 1990
PubMed
Summary
This summary is machine-generated.

This study discusses insulin therapy for type I diabetes and oral hypoglycemics for type II diabetes. Proper patient education and glycemic control are crucial for managing diabetes complications.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A note on the mapping and quantification of the human brain corticospinal tract.

European journal of radiology·2014
Same author

Enhancing patient-provider communication for long-term post-stroke spasticity management.

Acta neurologica Scandinavica·2013
Same author

Robotic training and clinical assessment of forearm and wrist movements after incomplete spinal cord injury: a case study.

IEEE ... International Conference on Rehabilitation Robotics : [proceedings]·2012
Same author

Robotic training and kinematic analysis of arm and hand after incomplete spinal cord injury: a case study.

IEEE ... International Conference on Rehabilitation Robotics : [proceedings]·2012
Same author

Intrathecal baclofen in the management of post-stroke hypertonia: current applications and future directions.

Acta neurochirurgica. Supplement·2007
Same author

Efficacy of early use of intrathecal baclofen therapy for treating spastic hypertonia due to acquired brain injury.

Brain injury·2005
Same journal

Primary Care at the Center of America's Mental Health Landscape.

Primary care·2026
Same journal

We Care, and We Will Listen.

Primary care·2026
Same journal

Addressing Sexual Health in Primary Care.

Primary care·2026
Same journal

Diagnosis and Management of Eating Disorders in Adolescents and Young Adults.

Primary care·2026
Same journal

Management of Concomitant Mental Health Conditions in Older Adults with Cognitive Impairment.

Primary care·2026
Same journal

Nonpharmacologic Management of Insomnia Disorder in Primary Care.

Primary care·2026
See all related articles

Area of Science:

  • Endocrinology
  • Pharmacology

Background:

  • Type I diabetes management relies solely on insulin, while type II diabetes can utilize insulin or oral hypoglycemics alongside lifestyle changes.
  • C-peptide levels help determine residual pancreatic endocrine function.

Purpose of the Study:

  • To outline current approaches to insulin therapy initiation and management for type I diabetes.
  • To review oral hypoglycemic agents, specifically sulfonylureas, for type II diabetes treatment.
  • To emphasize the importance of patient education and glycemic control in diabetes management.

Main Methods:

  • Initial insulin dosing recommendations (0.5 U/kg intermediate-acting human insulin).
  • Monitoring blood glucose levels to adjust insulin dosage and regimen.
  • Review of sulfonylurea drug classes (first and second generation) for type II diabetes.

Related Experiment Videos

Main Results:

  • Intensive insulin therapy is common for plasma glucose control.
  • Strict glycemic control may reduce macrovascular complications, but evidence for microvascular benefits is conflicting.
  • Sulfonylureas (tolbutamide, chlorpropamide, glyburide, glipizide) are the primary oral agents for type II diabetes in the US, with varying potencies and side-effect profiles.

Conclusions:

  • Patient education on insulin regimens, monitoring, diet, exercise, and foot care is essential for adequate diabetes control.
  • Balancing tight glycemic control benefits against hypoglycemia risks is necessary.
  • Second-generation sulfonylureas generally have fewer drug interactions than first-generation agents.